Difference between revisions of "Axitinib (Inlyta)"
(Created page with "'''FDA approved 1/27/2012''' Also known as AG013736. ==General information== Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascula...") |
m |
||
| Line 9: | Line 9: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://www.inlyta.com/ | + | *[http://www.inlyta.com/pdf/INLYTA_PatientInformation.pdf Axitinib (Inlyta) patient information (Pfizer)]<ref>[http://www.inlyta.com/pdf/INLYTA_PatientInformation.pdf Axitinib (Inlyta) patient information (Pfizer)]</ref> |
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 21:59, 21 February 2012
FDA approved 1/27/2012 Also known as AG013736.
General information
Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].